Effect of kurarinol on peripheral blood CTL surface PD-1 expression of patients with chronic hepatitis B
10.3760/cma.j.issn.1003-9279.2012.06.014
- VernacularTitle:苦参素对慢性乙型肝炎患者外周血CTL表面PD-1表达的影响
- Author:
Yin-Fang ZHU
1
;
Xi-Bing GU
;
Xiao-Juan YANG
;
Zhong HUA
;
Zhong-Hua LU
;
Bo ZANG
;
Hang-Yuan WU
;
Yi-Ming JIANG
;
Hao-Kun CHEN
;
Hao PEI
;
Yue-Qin XU
Author Information
1. 214005,无锡市传染病医院
- Keywords:
Kurarinol;
Hepatitis B,chronic;
Receptors,antigen,T-cell;
T Lymphocytes,cytotoxic
- From:
Chinese Journal of Experimental and Clinical Virology
2012;26(6):446-449
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the anti-viral mechanism of kurarinol through studying its influence on cytotoxic T lymphocyte (CTL) surface program death receptor-1 (PD-1) expression of patients with chronic hepatitis B (CHB).Methods 69 cases of CHB,HBV DNA ≥ 104 copies/ml,HBeAg positive,human leukocyte antigen (HLA)-A2 positive,alanine aminotransferase (ALT) ＞ 2 × upper limit of normal value(ULN).69 cases were randomly divided into two groups:34 cases in treatment group,600 mg of kurarinol glucose injection was used for intravenous dripping,once a day,one month later,200 mg of kurarinol capsule was used orally,three times a day and.200 mg of silybin meglumine tablet was used orally,three times a day.35 cases in control group,only silibin meglumine tablet was used,method and dosage were the same as those of treatment group.Three months later,their peripheral blood HBV specific CTL surface PD-1 expression,non-specific CTL surface PD-1 expression and level of HBV specific CTL,HBV DNA and HBeAg negative rate and liver functions were analyzed and compared.Results 3 months after treatment,peripheral blood HBV specific CTL surface PD-1 expression of the treatment group decreased compared with that before treatment(t =2.39,P ＜ 0.05),it also decreased compared with that of the control group 3 months after treatment(t =2.26,P ＜ 0.05),HBV specific CTL increased compared with that before treatment(t =3.01,P ＜ 0.01),it also increased compared with that of the control group after treatment (t =2.65,P ＜0.05).There was no significant difference of non-specific CTL surface PD-1 expression compared with that before treatment(P ＞ 0.05),and there was no significant difference compared with that of the control group after treatment(P ＞ 0.05).HBV DNA of 11 cases (32.5％) turned negative (HBV DNA ＜ 500 copies/ml),higher than that of the control group after treatment(2 cases,5.71％)x2 =7.99,P ＜ 0.01,H BeAg of 9 cases(26.47％) turned negative,higher than that of the control group after treatment(1 case,2.86％),x2 =7.75,P ＜ 0.01.Conclusion Kurarinol can increase level of HBV specific CTL by down-regulating peripheral blood HBV specific CTL surface PD-1 expression of CHB patients,which may be one of the possible mechanisms that kurarinol can remove or inhibit HBV of CHB patients.
